-
Aihara H, Miyazaki J, 1998: Gene transfer into muscle by electroporation in vivo[J]. Nat Biotechnol, 16, 867-870. doi: 10.1038/nbt0998-867
-
Arvin A M, Fast P, Myers M, Plotkin S, Rabinovich R, 2004: Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee[J]. Clin Infect Dis, 39, 233-239. doi: 10.1086/421999
-
Boeckh M, Geballe A P, 2011: Cytomegalovirus: pathogen, paradigm, and puzzle[J]. J Clin Invest, 121, 1673-1680. doi: 10.1172/JCI45449
-
Britt W J, Mach M, 1996: Human cytomegalovirus glycoproteins[J]. Intervirology, 39, 401-412. doi: 10.1159/000150510
-
Britt W J, Boppana S, 2004: Human cytomegalovirus virion proteins[J]. Hum Immunol, 65, 395-402. doi: 10.1016/j.humimm.2004.02.008
-
Brune W, Hengel H, and Koszinowski U H. 2001. A mouse model for cytomegalovirus infection. Curr Protoc Immunol, Chapter 19: Unit 19 17.
-
Chen J J, Huang S P, Chen Z, 2010: Human cellular protein nucleoporin hNup98 interacts with influenza A virus NS2/nuclear export protein and overexpression of its GLFG repeat domain can inhibit virus propagation[J]. J Gen Virol, 91, 2474-2484. doi: 10.1099/vir.0.022681-0
-
Geoffroy F, Moachon N, Rodwell J, Quash G A, 1996: Murine cytomegalovirus inactivated by sodium periodate is innocuous and immunogenic in mice and protects them against death and infection[J]. Vaccine, 14, 1686-1694. doi: 10.1016/S0264-410X(96)00116-8
-
Griffiths P D, 2002: The 2001 Garrod lecture[J]. The treatment of cytomegalovirus infection. J Antimicrob Chemother, 49, 243-253. doi: 10.1093/jac/49.2.243
-
Hobom U, Brune W, Messerle M, Hahn G, Koszinowski U H, 2000: Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes[J]. J Virol, 74, 7720-7729. doi: 10.1128/JVI.74.17.7720-7729.2000
-
Jons A, Dijkstra J M, Mettenleiter T C, 1998: Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex[J]. J Virol, 72, 550-557.
-
Khanna R, Diamond D J, 2006: Human cytomegalovirus vaccine: time to look for alternative options[J]. Trends Mol Med, 12, 26-33. doi: 10.1016/j.molmed.2005.11.006
-
Krzyzaniak M, Mach M, Britt W J, 2007: The cytoplasmic tail of glycoprotein M (gpUL100) expresses trafficking signals required for human cytomegalovirus assembly and replication[J]. J Virol, 81, 10316-10328. doi: 10.1128/JVI.00375-07
-
Lazzarotto T, Lanari M, 2011: Why is cytomegalovirus the most frequent cause of congenital infection?[J]. Expert Rev Anti Infect Ther, 9, 841-843. doi: 10.1586/eri.11.109
-
Loomis R J, Lilja A E, Monroe J, Balabanis K A, Brito L, Palladino G, Franti M, Mandl C W, Barnett S W, Mason P W, 2012: Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies[J]. Vaccine, 31, 919-926.
-
Mach M, Kropff B, Dal Monte P, Britt W, 2000: Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)[J]. J Virol, 74, 11881-11892. doi: 10.1128/JVI.74.24.11881-11892.2000
-
Mach M, Kropff B, Kryzaniak M, Britt W, 2005: Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects[J]. J Virol, 79, 2160-2170. doi: 10.1128/JVI.79.4.2160-2170.2005
-
Mach M, Osinski K, Kropff B, Schloetzer-Schrehardt U, Krzyzaniak M, Britt W, 2007: The carboxy-terminal domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis[J]. J Virol, 81, 5212-5224. doi: 10.1128/JVI.01463-06
-
Manley K, Anderson J, Yang F, Szustakowski J, Oakeley E J, Compton T, Feire A L, 2011: Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions[J]. Cell Host & Microbe, 10, 197-209.
-
Pass R F, Zhang C P, Evans A, Simpson T, Andrews W, Huang M L, Corey L, Hill J, Davis E, Flanigan C, Cloud G, 2009: Vaccine prevention of maternal cytomegalovirus infection[J]. New England Journal of Medicine, 360, 1191-1199. doi: 10.1056/NEJMoa0804749
-
Qureshi M H, Garvy B A, Pomeroy C, Inayat M S, Oakley O R, 2005: A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: Effects of virus-induced immunomodulation on disease progression[J]. Virus Research, 114, 35-44. doi: 10.1016/j.virusres.2005.05.008
-
Scalzo A A, Forbes C A, Davis-Poynter N J, Farrell H E, Lyons P A, 1995: DNA sequence and transcriptional analysis of the glycoprotein M gene of murine cytomegalovirus[J]. J Gen Virol, 76, 2895-2901.
-
Schleiss M R, Heineman T C, 2005: Progress toward an elusive goal: current status of cytomegalovirus vaccines[J]. Expert Rev Vaccines, 4, 381-406. doi: 10.1586/14760584.4.3.381
-
Shen S, Wang S, Britt W J, Lu S, 2007: DNA vaccines expressing glycoprotein complex Ⅱ antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates[J]. Vaccine, 25, 3319-3327. doi: 10.1016/j.vaccine.2007.01.011
-
Shimamura M, Mach M, Britt W J, 2006: Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response[J]. J Virol, 80, 4591-4600. doi: 10.1128/JVI.80.9.4591-4600.2006
-
Sung H, Schleiss M R, 2010: Update on the current status of cytomegalovirus vaccines[J]. Expert Rev Vaccines, 9, 1303-1314. doi: 10.1586/erv.10.125
-
Tandon R, Mocarski E S, 2012: Viral and host control of cytomegalovirus maturation[J]. Trends Microbiol, 20, 392-401. doi: 10.1016/j.tim.2012.04.008
-
Wang D, Shenk T, 2005: Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism[J]. Proc Natl Acad Sci U S A, 102, 18153-18158. doi: 10.1073/pnas.0509201102
-
Zhong J, Khanna R, 2007: Vaccine strategies against human cytomegalovirus infection[J]. Expert Rev Anti Infect Ther, 5, 449-459. doi: 10.1586/14787210.5.3.449